welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Jacques P. Tremblay, PhD
Department of Molecular Medicine
Faculty of Medicine, Université Laval
2705, Boulevard Laurier
Dr. Tremblay’s laboratory is renowned for his work on the transplantation of normal allogeneic myoblasts as a treatment for DMD. His Phase I clinical trial for this therapy showed that this transplant restores the expression of this protein in the patient’s muscle fibers.
In 2006, Dr. Tremblay received the Henry Friesen Award from the Royal College of Physicians and Surgeons of Canada for his work on the DMD therapy. His group is currently conducting a Phase I / II clinical trial on this therapy. In addition, his group is currently using CRISPR / Cas9 technology to correct the dystrophin gene, creating an additional deletion to produce a hybrid exon of the dystrophy gene, which not only restores the expression of dystrophin but also produces dystrophin with a normal structure.
Jacques P. Tremblay received a BSc in Biochemistry from McGill University in 1970, and a PhD in Neuroscience from UCSD (University of California in San Diego) in 1974. From 1975 to 1976, he was a postdoctoral fellow at the Laboratory of Neurobiology of l’Hôpital de l’Enfant-Jésus. Subsequently, he spent his entire career at Laval University.
Upgrading the toolbox for Duchenne muscular dystrophy research with a new rabbit modelResearch to improve our understanding of...
Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular DystrophyThis study is single arm, single center ...
Gene editing emerges as a new therapeutic strategy for Duchenne muscular dystrophyAdvances in gene editing technology have...
Champions to CureDuchenne Gala 2018https://www.youtube.com/watch?v=cmXFoPKU...
Gene Editing CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophyhttps://www.youtube.com/watch?v=8xNh1qr4...
Small Mutation Screening in the DMD Gene by Whole Exome Sequencing of an Argentine Duchenne/Becker Muscular Dystroph...Dystrophinopathies are neuromuscular X-l...
NCATS, FDA Co-Host Workshop on Gene Therapy for Rare Diseases“We are now at the point of translatin...